GHK-Cu dosing and formulations: topical, subcutaneous, and the concentration ranges in published research
GHK-Cu is administered in research protocols through two main routes: topical (in cosmetic-grade formulations and in higher-concentration research vehicles) and subcutaneous research-injection. The dose ranges differ by route and by the research endpoint being measured. The published literature covers both, and the concentration ranges are well-defined.
Topical-formulation concentration ranges
The published topical-research and cosmetic-formulation literature consolidates around three concentration bands:
- 0.05-0.1% (0.5-1 mg/mL). The “consumer cosmetic” concentration band. Skin-appearance endpoints in published clinical-formulation studies typically use this range over 4-12 week study periods. Carrier vehicles vary; the lower concentration is sometimes combined with other actives in a single formulation.
- 0.1-0.3% (1-3 mg/mL). The “higher-end cosmetic” concentration band. Used in research formulations with more aggressive endpoints (wrinkle depth measurement, biopsy-confirmed dermal collagen). The cost per gram of formulation rises sharply at this concentration.
- 0.3-0.5% (3-5 mg/mL). Research-grade topical concentration. Used in animal-model topical wound-recovery research and in some high-concentration research formulations.
Above 0.5%, the formulation chemistry becomes problematic — the copper component can produce vehicle-stability issues and the higher concentration does not produce proportionally greater downstream effects in the published assays. Higher-concentration topical formulations are uncommon in the published literature.
Subcutaneous research-protocol concentrations
Subcutaneous research with reconstituted GHK-Cu uses a different concentration range. The reconstituted vial is typically 1-5 mg/mL — researchers determine the per-protocol dose based on the research endpoint and the species being studied.
Published animal-model research protocols (rodent and rabbit wound-recovery models) typically use daily or alternate-day administration at total doses in the 0.1-1 mg/kg range. Human subcutaneous-research protocols are less standardised and the published data is thinner; most human in-vivo GHK-Cu research has used topical formulations rather than subcutaneous administration.
Reconstitution math and the blue colour
Reconstituted GHK-Cu is characteristically blue — the copper(II) complex absorbs in the red end of the visible spectrum, producing a clear blue solution at 1-5 mg/mL concentration. This colour is expected and is the simplest visual confirmation that the copper component is intact in the reconstituted material. A clear-colourless reconstituted solution is unusual and may indicate copper-component absence (uncomplexed GHK is colourless).
Reconstitution math for a typical 50 mg GHK-Cu vial:
- 50 mg / 10 mL bacteriostatic water = 5 mg/mL. A 2 mg dose is 0.4 mL = 40 units on a U-100 insulin syringe. A 5 mg dose is 1.0 mL = 100 units (full 100u syringe).
- 50 mg / 5 mL bacteriostatic water = 10 mg/mL. A 2 mg dose is 0.2 mL = 20 units; a 5 mg dose is 0.5 mL = 50 units.
- 50 mg / 50 mL bacteriostatic water = 1 mg/mL. Suitable for low-dose protocols or for further dilution into topical-vehicle formulations.
The free reconstitution calculator handles the unit conversion for non-standard reconstitution volumes. The storage and handling guide covers the protocol in more depth.
UAE research-supply note
Wellness Labs supplies GHK-Cu as research-grade lyophilised powder in 50 mg vials. Each batch ships with HPLC purity verification (≥98%), mass-spectrometry confirmation of the parent ion, and atomic-absorption spectroscopy confirmation of the copper content per batch. Cold-chain shipping across the UAE; same-day Dubai delivery, next-business-day across the rest of the UAE.
Further reading
- GHK-Cu parent overview.
- GHK-Cu mechanism deep-dive.
- GHK-Cu vs other skin-research peptides.
- GHK-Cu side effects and tolerability.
- GHK-Cu storage and handling.
- Free reconstitution calculator.
Last reviewed 2 June 2026. Editorial inbox: info@uaewellnesslab.com.
Frequently asked questions
- What concentration is used in topical GHK-Cu research formulations?
- Published topical-formulation research uses GHK-Cu at 0.05% to 0.5% w/v. Cosmetic-science formulations typically sit in the 0.05-0.2% range; research-protocol formulations may go higher. The dermal-penetration data plateaus above approximately 0.5% — higher concentrations do not produce proportionally greater dermal-fibroblast exposure.
- What concentration is used in subcutaneous GHK-Cu research?
- Subcutaneous research protocols typically reconstitute GHK-Cu at 1-5 mg/mL with bacteriostatic water. A typical 50 mg vial reconstituted with 5 mL produces a 10 mg/mL solution; with 10 mL, a 5 mg/mL solution. Dose volume on a U-100 insulin syringe follows the standard reconstitution math.
- Why is reconstituted GHK-Cu blue?
- The blue colour comes from the copper(II) component of the GHK-Cu complex. It is a visual confirmation that the copper coordination is intact in solution. Loss of blue colour or shift toward green or brown indicates oxidation or copper-component degradation; reconstituted GHK-Cu should remain clearly blue throughout the research-protocol re-entry window.
- How is the dose drawn on a U-100 insulin syringe for GHK-Cu?
- U-100 syringes read in units where 100 units = 1 mL. For a 50 mg GHK-Cu vial reconstituted in 5 mL (10 mg/mL = 10,000 μg/mL), a 1 mg dose is 0.1 mL = 10 units; a 2 mg dose is 0.2 mL = 20 units. The 30-unit insulin syringe size provides the cleanest precision for small-volume draws. The free reconstitution calculator at /tools/reconstitution-calculator handles the math.
- What duration is used in GHK-Cu research protocols?
- Topical-formulation research protocols range from 4 weeks (cell-system endpoints) to 12-24 weeks (in-vivo skin-research endpoints). Subcutaneous research protocols are less standardised and typically range 4-12 weeks. The dermal-effect endpoints (collagen and elastin response in skin biopsy or imaging) require longer protocols than the gene-expression endpoints (4-8 weeks).